Bicara Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BCAX Nasdaq 2834 www.bicara.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bicara Therapeutics Inc.

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sep 3rd, 2026 6:30 am
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul - Aug 19th, 2026 7:56 am
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript - Aug 18th, 2026 9:13 am
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Aug 14th, 2026 6:30 am
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX) - Aug 13th, 2026 4:10 am
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says - Aug 11th, 2026 11:28 am
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Aug 11th, 2026 11:15 am
Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances - Aug 11th, 2026 8:17 am
Bicara Therapeutics Q2 Earnings Call Highlights - Aug 11th, 2026 8:04 am
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth - Aug 11th, 2026 5:30 am
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET - Aug 4th, 2026 6:30 am
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors - Jul 28th, 2026 6:30 am
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - Jun 12th, 2026 11:21 pm
Bicara (BCAX) Q4 2025 Earnings Transcript - Jun 1st, 2026 10:13 am
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer - May 22nd, 2026 9:09 am
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC - May 21st, 2026 3:00 pm